Cardiolinc was founded in 2014 by biologist Dr. Yvan Devaux, Head of the Cardiovascular Research Unit of the Luxembourg Institute of Health, on the belief that regulatory RNA research in cardiovascular disease could move faster by collaboration. Thus, Cardiolinc serves as a platform to provide opportunities for scientific collaboration, where coordinating efforts from different groups will maximize the potential of research in this developing field.
Through Cardiolinc, these researchers and clinicians are able to find one another, exchange knowledge, share ideas, and build projects towards a common goal, fight cardiovascular disease, the main killer in the world. The network has grown quickly and to provide new perspectives for the network, including sustainability, in 2017 it was registered in Luxembourg as a non-profit organization (NPO).
Yvan Devaux, PhD
My background training is in Biological Sciences, focusing on Biology and Health during my PhD and later becoming a Research Assistant at the Department of Pulmonary and Critical Care Medicine of the University of Pittsburgh, USA, working on the same topic. When returning to France, I assumed a Research Assistant position at INSERM, University of Medicine, Nancy, before joining the Luxembourg Institute of Health (LIH) as a researcher in 2005. As head of the Cardiovascular Research Unit, my main interest is the discovery and validation of novel RNA biomarkers and therapeutic targets of cardiac disease. Since my research is translational and I believe that collaboration can forward this area of research, I founded the Cardiolinc network to bring together complementary expertise from clinicians, basic researchers, statisticians, bioinformaticians, systems biologists, and industrials, towards the satisfaction of unmet medical needs.
I have a background in Biological Sciences and Biotechnology, with expertise in Molecular Biology. During my PhD studies in Brazil and USA, at the Institute for Systems Biology, I specialized in Epigenetics of physical exercise and focused on microRNA research. Before joining the Cardiovascular Research Unit at the Luxembourg Institute of Health (LIH), I lectured Molecular Biology and Biochemistry at Centro Universitário do Distrito Federal – UDF, Brazil, and co-founded the Instituto Ciência para Saúde (Science for Health Institute), which aims to communicate scientific research and innovation applied to disease prevention and treatment. I have a passion for inspiring young people to study science by breaking down academic and cultural barriers and to educate the general public about how science works. Currently, I develop translational research on cardiovascular disease and RNA-based biomarkers and as coordinator of the Cardiolinc network, I facilitate and initiate collaborations to advance research in cardiovascular disease and improve human health.
Costanza Emanueli, PhD, Professor, BHF Chair of Cardiovascular Science
My background is in pharmacology and therapeutic angiogenesis. Although I am a basic scientist, all of my past mentors were clinical academics and I have always been embedded in clinical institutes. This was later proven a true advantage and my research is now largely translational, aiming at providing new therapeutic options for patients suffering from cardiovascular disease. My programme focuses on both “causes” and “solutions”, where I am part of local, national and international research networks, including the NIHR Bristol BRU in cardiovascular disease, the new British Heart Foundation centre of vascular regenerative medicine (as its Bristol coordinator) and a Leducq Transatlantic network in vascular microRNA (as the Bristol PI). I am engaged with several national and international collaborations aimed at improving cardiovascular and stem cell research and training.
Iain B Squire, MD, Professor, MBChB, FRCP, FESC
I qualified from Glasgow University, where I trained and held the position of Lecturer. Later, I became Senior Lecturer in Medicine and Therapeutics at the University of Leicester. From studies of the mechanisms by which congestive heart failure develops after acute myocardial infarction (Matrix metalloproteinase research), to the utility of biomarkers in prognostication (natriuretic peptides and other markers), to the epidemiology of heart failure (trends in prognosis), I have pioneered the growing reputation of Leicester as a centre of excellence across a number of aspects of heart failure research. I have also led the extension of many aspects of our heart failure research to related areas of cardiovascular disease. In particular, we have investigated the use of biomarkers in community screening for heart failure, and in prognostication after myocardial infarction.
Stephane Heymans, MD, PhD, Professor, FESC, FHFA, chair of Cardiomyopathies
I am a cardiologist and research scientist since 2003 focusing on the molecular mechanisms of heart failure, looking at the interplay between inflammatory cells, fibroblasts, and cardiomyocytes. Unraveled the key role of structural and non-structural matrix proteins and RNAs, including microRNAs, matrix metalloproteinases, collagens and matri-cellular proteins, in mediating cardiac inflammation, fibrosis and dysfunction. After my MD PhD at the University of Leuven, Belgium, and short stays in Berlin, Paris, London, and Trieste, I became a staff member of Cardiology since 2003 at the Maastricht University Medical Centre. Later appointed professor within the Netherlands Heart Institute, the Maastricht University Medical Centre, and the University of Leuven, my heart failure research focuses on heart with preserved ejection fraction and dilated cardiomyopathies. I have expertise in conducting clinical and basic research projects and starting up new clinical trials. The clinical care program and related cohorts I developed allow a continuous translation between the bench and the bedside.
I am a board member at the European Heart Failure Association, Chair of the Committee on Translational Research of the European Heart Failure Association, Chair of the Working Group on Myocardial Function of the European Society of Cardiology.